Litcius/Paper detail

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias, Ian D. Davis, Maria De Santis, Eiji Kikuchi, Xavier García del Muro, Ugo De Giorgi, Marina Mencinger, Kouji Izumi, Stefano Panni, Mahmut Gümüş, Mustafa Özgüroğlu, Arash Rezazadeh Kalebasty, Se Hoon Park, B. Yа. Alekseev, Fabio A. Schutz, Jian-Ri Li, Dingwei Ye, Nicholas J. Vogelzang, Sandrine Bernhard, Darren Tayama, Sanjeev Mariathasan, Almut Mecke, AnnChristine Thåström, Enrique Grande

2020The Lancet788 citationsDOIOpen Access PDF

Topics & Concepts

AtezolizumabMedicineMetastatic Urothelial CarcinomaPlaceboCarboplatinGemcitabineChemotherapyInternal medicineUrologyOncologyCisplatinCancerBladder cancerPembrolizumabUrothelial carcinomaImmunotherapyPathologyAlternative medicineBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial | Litcius